おすすめの製品
品質水準
アッセイ
≥98% (HPLC)
形状
solid
メーカー／製品名
Calbiochem®
保管条件
OK to freeze
desiccated
不純物
≤10 EU/mg Endotoxin (dry weight)
色
white to off-white
溶解性
methanol: 20 mg/mL
water: 50 mg/mL
輸送温度
ambient
保管温度
−20°C
InChI
1S/C22H29N7O5.2ClH/c1-28(2)19-17-20(25-10-24-19)29(11-26-17)22-18(31)16(15(9-30)34-22)27-21(32)14(23)8-12-4-6-13(33-3)7-5-12;;/h4-7,10-11,14-16,18,22,30-31H,8-9,23H2,1-3H3,(H,27,32);2*1H/t14-,15+,16?,18+,22+;;/m0../s1
InChI Key
MKSVFGKWZLUTTO-USYAMCSGSA-N
詳細
An aminonucleoside antibiotic that acts as a prokaryotic and eukaryotic protein synthesis inhibitor. Resembles the aminoacyl-adenylyl terminus of aminoacyl-tRNA and competes for binding to the "A site" of the large ribosomal subunit. Its incorporation into a growing polypeptide results in termination of chain elongation and release of the nascent polypeptidyl-puromycin. Useful for selection of mammalian cell lines expressing a transfected pac gene (Streptomyces alboniger), whose product puromycin acetyltransferase, inactivates the drug via acetylation. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells. Recommended range for selection of transfected mammalian cells ranges from 1 to 30 µg/ml.
Protein synthesis inhibitor. Inhibits translation by causing premature release of nascent polypeptide chains. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells.
Puromycin, CAS 58-58-2, is a protein synthesis inhibitor that causes premature release of nascent polypeptide chains.
生物化学的／生理学的作用
Primary Target
protein synthesis
protein synthesis
警告
Toxicity: Harmful (C)
再構成
Following reconstitution, sterilize by filtration through a 0.22 µm pore-size filter, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
その他情報
Chow, S.C., et al. 1995. Exp. Cell Res.216, 149.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Chow, S.C., et al. 1991. Exp. Cell Res. 216, 149.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Chow, S.C., et al. 1991. Exp. Cell Res. 216, 149.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
540411R-100MG:
540411-25MG:
540411R-VMG:
540411-VMG:
540411-100MG:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
この製品を見ている人はこちらもチェック
Marta Alenquer et al.
PLoS pathogens, 17(8), e1009772-e1009772 (2021-08-06)
Understanding SARS-CoV-2 evolution and host immunity is critical to control COVID-19 pandemics. At the core is an arms-race between SARS-CoV-2 antibody and angiotensin-converting enzyme 2 (ACE2) recognition, a function of the viral protein spike. Mutations in spike impacting antibody and/or
Juliana Gonçalves et al.
Cell reports. Medicine, 2(12), 100468-100468 (2021-12-08)
In view of the scarcity of data to guide decision making, we evaluated how BNT162b2 and mRNA-1273 vaccines affect the immune response in lactating women and the protective profile of breastmilk. Compared with controls, lactating women had a higher frequency
Jianxiang Lin et al.
Cell proliferation, 54(8), e13096-e13096 (2021-07-10)
PKM1 and PKM2, which are generated from the alternative splicing of PKM gene, play important roles in tumourigenesis and embryonic development as rate-limiting enzymes in glycolytic pathway. However, because of the lack of appropriate techniques, the specific functions of the
Baolong Xia et al.
Nature protocols, 15(10), 3478-3498 (2020-09-23)
Precise and efficient genome modifications provide powerful tools for biological studies. Previous CRISPR gene knockout methods in cell lines have relied on frameshifts caused by stochastic insertion/deletion in all alleles. However, this method is inefficient for genes with high copy
Jingchun Zhang et al.
Journal of Cancer, 13(1), 225-242 (2022-01-04)
MARVEL domain-containing 1 (MARVELD1) is one of the MARVEL domain-containing proteins. Expression of MARVELD1 in tumor and non-tumor tissues, the relationship between its expression and cancer prognosis, and upstream regulation of MARVELD1 were examined using pan-cancer data from The Cancer
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）